Category: Technology Licenses
Created On: 2022-04-28
Record Count: 12
- cell therapy
- bone marrow
- Stem cells
- Drug Discovery
- Wound Care
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 213098
Graft-versus-host disease (GvHD) is a medical complication following the receipt of transplanted tissue from a genetically different person. GvHD is commonly associated with stem cell transplant (bone marrow transplant), but the term also applies to other forms of tissue graft. Immune cells (white blood cells) in the donated tissue (the graft) recognize the recipient (the host) as foreign (nonself).
IPSCIO Record ID: 59717
IPSCIO Record ID: 346226
Aallogeneic hematopoietic stem cell transplantation (allo-HSCT), called Facilitated Allo-HSCT Therapy.
The product candidate, FCR001, which is central to Facilitated Allo-HSCT Therapy, is a novel allogeneic cell therapy comprised of stem and immune cells that are procured from a healthy donor, who is also the organ donor in the case of organ transplantation. FCR001 is rapidly processed in the GMP facility using proprietary manufacturing methods. Then, at the time of the transplant, FCR001 is administered to the recipient following nonmyeloablative conditioning, which is designed to be less toxic than myeloablative conditioning. A fully myeloablative conditioning regimen consists of a combination of agents and high doses of total body irradiation that destroy hematopoietic stem cells (HSCs) in the bone marrow and results in profound depletion of HSC-derived cells within one to three weeks following administration that is irreversible, and in most instances is fatal unless rescued by a stem cell transplant. The nonmyeloablative conditioning for FCR001 entails lower doses of chemotherapy and total body irradiation, causes less depletion of blood cells and does not require stem cell support for the recipient to resume the production of blood cells and platelets.
Allo-HSCT Therapy has the potential to treat a range of severe autoimmune diseases and severe non-malignant blood, immune and metabolic disorders, in each case with potential for similar outcomes to what has previously been observed with HSCT, while mitigating the toxicities, morbidities and extended hospital stay associated with the conditioning regimen typically required by HSCT.
Facilitated Allo-HSCT Therapy could prevent organ rejection without the morbidity and mortality that has been associated with the use of lifelong anti-rejection medicines, also known as chronic immunosuppression.
IPSCIO Record ID: 383612
Chondrogen shall mean any formulation, dosage form or delivery system that contains culturally expanded, undifferentiated, unmodified human MSCs for local delivery for the Articulating Orthopedic Indication and any Improvements thereto.
Prochymal shall mean any formulation, dosage form or delivery system suitable for Vascular Administration that contains culturally expanded, undifferentiated, unmodified human MSCs, and any Improvements thereto.
Ulcerative Colitis Indication shall mean the use of Prochymal for the treatment or prevention of ulcerative colitis.
Mesenchymal Stem Cells or MSCs shall mean the human formative pluripotential blast cells found inter alia in bone marrow, blood, dermis and periosteum that are capable of differentiating into any of the specific types of mesenchymal or connective tissues.
COPD Indication shall mean the use of Prochymal to treat chronic obstructive pulmonary disease.
Articulating Orthopedic Indication shall mean the use of Chondrogen for preventing or treating diseases, defects or conditions of articulating joints, including cartilage and meniscus repair, osteoarthritis, osteochondral defect repair, and the treatment of acute and chronic orthopedic pain within an articulating joint.
Crohns Indication shall mean the use of Prochymal to treat Crohns disease.
Diabetes Indication shall mean the use of Prochymal for the prevention or treatment of Type I diabetes.
GvHD Indication shall mean the use of Prochymal to treat or prevent graft versus host disease.
Cardiac Indication shall mean the use of Prochymal to treat or prevent acute myocardial infarction.
Pain Therapeutic shall mean use of Chondrogen for the mitigation or relief of orthopedic pain with a Statistically Significant duration of relief of at least one year.
IPSCIO Record ID: 335
The Licensor granted the Company an exclusive worldwide license under the licensed information and the patents for the development, manufacture and sale of the products.
Our Veto-Cell technology is a next generation cell-therapy technology that enables the selective attenuation of the immune system. In other words, pre-clinical studies suggest that the treatment has the ability to reduce the immune response to selective â€œthreats,â€ with low risk for adverse side effects.
IPSCIO Record ID: 27617
IPSCIO Record ID: 330906
Aging Frailty is a common geriatric condition that disproportionately increases a patientâ€™s risk for poor clinical outcomes due to disease and injury, and is widely believed by geriatricians to ultimately be treatable. MSCs are biological entities obtained from living humans that can pose risks to the recipient. MSC therapies require many manufacturing steps. Cells must be harvested from donor tissue, isolated, and expanded in cell culture to produce a sufficient number of cells for use. Each step carries risks for contamination by other cells, microbes, or adventitious agents. The transfer of cells into a recipient can also carry risks and complications associated with the procedure itself, and a recipient may reject the transplanted cells.
IPSCIO Record ID: 362432
This agreement includes a non-exclusive grant back from Licensee to Licensor.
Licensors Dimerizer shall mean the compound known as xx1903, all analogs and derivatives of xx1903 and any Dimerizcr or salt thereof, where the composition of matter thereof or its use as a divalent ligand is, at any time during the Primary License Term, within the scope of a claim in any patent or patent application within the Licensed Patent Rights.
xx1903 is for the treatment of GvHD as an orphan drug.
GvHD shall mean a clinical condition involving acute or chronic adverse effects or symptoms resulting from the allogenic transplantation of bone marrow, hematopoietic or stem cells into a human being in which engrafted donor cells attack the patients organs and tissues which can be treated by activating cell signaling leading to apoptosis of the transplanted cells.
Cell Transplantation Indication shall mean GvHD or any other acute or chronic adverse clinical effect in a human being resulting from transplantation of bone marrow, hematopoietic or stem cells that can be treated by inducing apoptosis of transplanted cells, or in the case of a bone marrow, hematopoietic or stem cell product for transplantation that includes cells containing a gene coding for an Inducible Caspase, any disease or condition in a human being that can be treated by such product.
Licensed Products include BPX-101 (formerly BP-GMAX-CDJ) , and, CaspaCIDe Donor Lymphocyte Infusion.
Licensee is developing cell therapies to treat cancers and other chronic and life-threatening diseases.
IPSCIO Record ID: 3624
IPSCIO Record ID: 29036
IPSCIO Record ID: 2550
A. ISSUED U.S. PATENTS
4,721,096 Process for Replicating Bone Marrow In Vitro and Using the Same
4,960,489 Three-Dimensional Cell and Tissue Culture System
5,032,508 Three-Dimensional Cell and Tissue Culture System
5,160,490 Three-Dimensional Cell and Tissue Culture System Apparatus
5,266,480 Three-Dimensional Skin Culture System
5,443,950 Three-Dimensional Cell and Tissue Culture System
5,460,939 Temporary Living Skin Replacement
5,478,739 Three-Dimensional Stromal Cell and Tissue Culture System
5,510,254 Three-Dimensional Cell and Tissue Culture System
5,512,475 Three-Dimensional Skin Cell and Tissue Culture System
5,516,680 Three-Dimensional Kidney Cell and Tissue Culture System
5,516,681 Three-Dimensional Pancreatic Cell and Tissue Culture System
5,518,915 Three-Dimensional Mucosal Cell and Tissue Culture System
5,541,107 Three-Dimensional Bone Marrow Cell and Tissue Culture System
5,559,022 Liver Reserve Cells
5,578,485 Three-Dimensional Blood-Brain Cell and Tissue Culture System
5,580,781 Three-Dimensional Tumor Cell and Tissue Culture System
5,599,788 Method for Accelerating Skin Wound Healing with H3 Protein
5,624,840 Three-Dimensional Liver Cell and Tissue Culture System
5,714,588 Enhancement of Cellular Attachment Using H3 Protein
5,763,267 Apparatus for the Large Scale Growth and Packaging of Cell
Suspensions and Three-Dimensional Tissue Cultures
5,785,964 Three-Dimensional Genetically Engineered Cell and Tissue Culture
5,792,603 Apparatus and Method for Sterilizing, Seeding, Culturing, Storing,
Shipping and Testing Tissue, Synthetic or Native, Vascular Grafts
5,827,729 Diffusion Gradient Bioreactor and Extracorporeal Liver Device
Using a Three-Dimensional Liver Tissue
5,830,708 Methods for Production of a Naturally Secreted Extracellular Matrix
5,842,477 Method for Preparing Cartilage
5,843,766 Apparatus for the Growth and Packaging of Three Dimensional
5,846,828 Apparatus and Method for Sterilizing, Seeding, Culturing,
Storing, Shipping and Testing Tissue, Synthetic, or Mechanical
Heart Valves or Valve Segments
5,849,588 Methods of Use of a Three-Dimensional Liver Cell and Tissue
5,858,721 Three-Dimensional Cell and Tissue Culture System
5,863,531 In Vitro Preparation of Tubular Tissue Structures by Stromal Cell
Culture on a Three-Dimensional Framework
5,902,741 Three Dimensional Cartilage Cultures
5,919,702 Production of Cartilage Tissue Using Cells Isolated From
5,928,945 Application of Shear Flow Stress to Chondrocytes or Chondrocytre
Stem Cells to Produce Cartilage
5,962,325 Three-Dimensional Stromal Tissue Cultures
6,008,049 Diffusion Gradient Bioreactor and Extra-Corporeal Liver Device
6,022,743 Three-Dimensional Culture of Pancreatic Parenchymal Cells
Cultured Living Stromal Tissue Prepared In Vitro
6,027,935 Gene Up-Regulated in Regenerating Liver
6,060,306 Apparatus and Method for Sterilizing, Seeding, Culturing, Storing,
Shipping and Testing Replacement Cartilage Tissue Constructs
6,121,042 Apparatus and Method for Simulating In Vivo Conditions While
Seeding And Culturing Three-Dimensional Tissue Constructs
6,140,039 Three-Dimensional Filamentous Tissue Having Tendon or Ligament
6,218,182 Method For Culturing Three-Dimensional Tissue in Diffusion
Gradient Bioreactor and Use Thereof
6,284,284 Compositions and Methods for Production and Use of an Injectable
Naturally Secreted Extracellular Matrix
6,291,240 Cells or Tissues With Increased Protein Factors and Method of
B. PENDING U.S. PATENT APPLICATIONS
08/488,165 Three-Dimensional Human Cell Cultures on Cardiac Valve Frameworks
and Their Uses – on appeal
08/660,787 Compositions and Methods for Production and Use of an Injectable,
Naturally Secreted Extracellular Matrix
09/256,649 Living Chimeric Skin Replacement
09/313,538 Conditioned Cell Culture Medium Compostions and Methods of Use
09/362,948 Genetically Engineered Cells Responsive to Environmental Cues
09/350,386 Human Naturally Secreted Extracellular Matrix-Coated Device and
Methods for the Production and Uses Thereof
09/401,445 Three Dimensional Human Cell Cultures on Cardiac Valve Frameworks
and Their Uses
09/411,585 Methods of Using a Three-Dimensional Stromal Tissue to Promote
09/457,519 Application of Shear Flow Stress to Smooth Muscle Cells for the
Production of Implantable Structures
09/482,203 Apparatus and Method for Sterilizing, Seeding, Cultiring, Storing,
Shipping and Testing Tissue Synthetic or Native Vascular Grafts
09/603,642 Monitorable Three Dimensional Scaffolds and Tissue Culture
09/724,410 Cells or Tissues with Increased Protein Factors and Methods for
09/847,902 Container for Shipping Tissue
60/297,177 Compositions Comprising Conditioned Cell Culture Media and Uses
II. UNITED STATES PATENTS LICENSED TO ADVANCED TISSUE SCIENCES, INC.
A. LICENSED FROM THE MASSACHUSETTS INSTITUTE OF TECHNOLOGY
4,418,691 Method of Promoting the Regeneration of Tissue at a Wound
4,458,678 Cell-Seeding Procedures Involving Fibrous Lattices
4,505,266 Method of Using a Fibrous Lattice
4,638,045 Non-Peptide Polyamino Acid Bioerodible Polymers
4,806,621 Biocompatible, Bioerodible, Hydrophobic, Implantable Polyamino
4,947,840 Biodegradable Templates for the Regeneration of Tissues
5,041,138 Neomorphogenesis of Cartilage In Vivo From Cell Culture
5,128,420 Method of Making Hydroxamic Acid Polymers From Primary Amide
5,399,665 Biodegradable Polymers For Cell Transplantation
5,514,378 Biocompatible Polymer Membranes and Methods of Preparation of Three
Dimensional Membrane Structures
5,516,532 Injectable Non-Immunogenic Cartilage and Bone Preparation
5,654,381 Functionalized Polyester Graft Copolymers
5,736,372 Biodegradable Synthetic Polymeric Fibrous Matrix Containing
Chondrocyte For In Vivo Production of a Cartilaginous Structure
5,759,830 Three-Dimensional Fibrous Scaffold Containing Attached Cells for
Producing Vascularized Tissue In Vivo
5,770,193 Preparation of Three-Dimensional Fibrous Scaffold For Attaching
Cells to Produce Vascularized Tissue In Vivo
5,770,417 Three-Dimensional Fibrous Scaffold Containing Attached Cells for
Producing vascularized Tissue In Vivo
5,804,178 Implantation of Cell-Matrix Structure Adjacent Mesentery, Omentum or
6,123,727 Tissue Engineered Tendons and Ligaments
6,095,148 Neuronal Stimulation Using Electrically Conducting Polymers
6,224,893 Semi-Interpenetrating or Interpenetrating Polymer Network for Drug
Delivery and Tissue Engineering
B. LICENSED FROM THE UNIVERSITY OF FLORIDA
5,650,299 Cells Producing Stem Cell Proliferation Factor
5,981,708 Stem Cell Proliferation Factor
IPSCIO Record ID: 383557
MSC shall mean human cells that are capable of differentiation into more than one mesenchymal lineage.
Product means any product or composition that contains MSC and/or any process or service performed with respect to recovery, expansion, maintenance, purification, storage, production, formulation or use of MSC.
The patents include
— Monoclonal antibodies specific for marrow-derived mesenchymal cells;
— Uses for non-autologus mesenchymal stem cells;
— Osteoporosis bond regeneration;
— Mesenchymal stem cells for prevention and treatment of immune responses in transplantation;
— Mesenchymal stem cells as immunosuppressants;
— Regulation of Hema topoietic stem cell differentiation by the use of human mesenchymal stem cells;
— Uses of fibroblasts or supernatants from fibroblasts for the suppression of immune responses in transplantation.
Hematologic malignancies are cancers that begin in blood-forming tissue, such as the bone marrow, or in the cells of the immune system. There are three main types of hematologic malignancies leukemia, lymphoma and multiple myeloma.